Undergraduate education

University of Michigan, BS, 1989

Years in MSTP

1989-1997

PhD

Human oncology, 1995

Mentor

V. Craig Jordan, PhD

Thesis title

Structural Characterization of Ligand-Estrogen Receptor-Deoxyribonucleic Acid Interaction

Residency

Obstetrics and gynecology, Duke University, 1998-2001

Fellowship

Reproductive Endocrinology and Fertility, NIH, 2001-2002

Current position

Professor, Department of Obstetrics and Gynecology; director, Division of Research, Uniformed Services University of the Health sciences

View profile

PhD publications

Levenson AS, Wolf DM, Catherino WH, Takei H, Jordan VC. Understanding the Antiestrogenic Actions of Raloxifene and a Mechanism of Drug Resistance to Tamoxifen. Breast Cancer. 1998 Apr 25;5(2):99-106. PMID: 11091634.

Levenson AS, Catherino WH, Jordan VC. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol. 1997 Mar;60(5-6):261-8. PMID: 9219916.

Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol. 1995 Nov;55(2):239-46. PMID: 7495704.

Catherino WH, Wolf DM, Jordan VC. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol. 1995 Aug;9(8):1053-63. PMID: 7476979.

Jordan VC, Catherino WH, Wolf DM. A mutant receptor as a mechanism of drug resistance to tamoxifen treatment. Ann N Y Acad Sci. 1995 Jun 12;761:138-47. PMID: 7625717.

Catherino WH, Jordan VC. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett. 1995 May 25;92(1):39-47. PMID: 7757959.

Catherino WH, Jordan VC. The biological action of cDNAs from mutated estrogen receptors transfected into breast cancer cells. Cancer Lett. 1995 Mar 23;90(1):35-42. PMID: 7720041.

Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer. 1993 May;67(5):945-52. PMID: 8494728; PMCID: PMC1968434.

Catherino WH, Jordan VC. A risk-benefit assessment of tamoxifen therapy. Drug Saf. 1993 May;8(5):381-97. PMID: 8504018.

Jordan VC, Jeng MH, Catherino WH, Parker CJ. The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer. 1993 Feb 15;71(4 Suppl):1501-5. PMID: 8431886.

Jordan VC, Catherino WL, Wolf DM. Drug-resistance to tamoxifen-mutant estrogen-receptors as a potential mechanism of tamoxifen-stimulated tumor growth. Endocrine-related Cancer. 1995 Mar;2(1):45-51.